CLINICAL_TRIALS
trial_result
· 2022-01-24
Clinical Trial Update: Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO) [Phase 2]
Summary
Phase 2 trial of RVT-1401 for Graves' Ophthalmopathy completed; results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Immunovant Sciences GmbH | Conditions: Graves' Ophthalmopathy | Phase 2 | Status: COMPLETED | Results posted: 2022-01-24